Prostate cancer: estimating the benefits of PSA screening - Wikidata - wikimedia - TriplyDB

Prostate cancer: estimating the benefits of PSA screening

Prostate cancer: estimating the benefits of PSA screening

http://www.wikidata.org/entity/Q33823085

about

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the alpha omega trial Common genetic variants in prostate cancer risk prediction--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3)Screening for prostate cancer: early detection or overdetection?Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis.Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer.

P2860

Q33835863-F2B67713-DA02-4876-90C7-5FA228649804 Q33937634-039E62E9-991F-4B19-BE37-CED288D07BBB Q34326169-CFA584DA-9DFE-4BEC-B8FE-48B250AD74EC Q35069651-97DFF8BE-2D49-4AF2-9401-8522E0E06107 Q35868793-0B48AB8E-CFB2-4506-8476-20BBFD8ED1F4 Q36152421-00A25665-C168-458F-9C02-0C1FF37961BF Q39559217-07728D4A-1211-46FA-A8C4-0A44588A2E6D Q40797430-446F29CF-D3DC-46DB-B2E9-7C53F2DA300F Q47573527-CA1B11B6-A331-4A9C-99C2-AE85A12B1C18

P2860

Prostate cancer: estimating the benefits of PSA screening

http://www.wikidata.org/entity/Q33823085

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Prostate cancer: estimating the benefits of PSA screening

@ast

Prostate cancer: estimating the benefits of PSA screening

@en

type

label

Prostate cancer: estimating the benefits of PSA screening

@ast

Prostate cancer: estimating the benefits of PSA screening

@en

prefLabel

Prostate cancer: estimating the benefits of PSA screening

@ast

Prostate cancer: estimating the benefits of PSA screening

@en

P1433

Q33823085-6BE8FD1C-D3F9-48D5-BDA7-79023ABDC1A1

P1476

Q33823085-2A4DFADB-72A7-4A9D-B447-111A4DF9D977

P2860

Q33823085-060186EF-7947-4590-B9B8-CEAB0C8F60C3

Q33823085-1821F491-3839-4318-80E3-8EEC6EB4A088

Q33823085-5459E5BD-8622-4BDB-9233-522EB7A5A70E

Q33823085-565171B5-A8DF-425F-96D3-3E64E3456A3A

Q33823085-59B00291-90E1-4FFF-94B7-7C798D4B0A4C

Q33823085-84C7B186-6754-4F80-8E2F-CBE380069112

Q33823085-B0F86B73-EB01-49B3-BE76-419732370189

Q33823085-D0E7F2ED-E63B-4B6C-B483-D9666909CDB0

P2888

Q33823085-702D1122-2DC3-4417-9A24-441727DD658D

P304

Q33823085-011A78EE-795F-41B0-A4F9-FC2345E49B97

P31

Q33823085-8BD9118B-FF92-4B25-BAAC-EBFF6A43981D

P356

Q33823085-2F50DCB2-29CC-4489-A638-EAF206979060

P407

Q33823085-A2613A2B-27E0-4BF7-A50E-0E9567E9A4E8

P433

Q33823085-E5492C8D-1062-4A5B-A96B-3BD2C088F3C2

P478

Q33823085-0D0721E0-814C-45D4-B3C3-485AD62C0587

P50

Q33823085-A15D84C0-8D76-4043-BB2C-E320346D1159

Q33823085-FD525C78-B2B6-48B0-AE51-5CC0FE742AAD

P577

Q33823085-F593D1EE-0B80-48B4-BAD7-5E1C042F0249

P5875

Q33823085-308C7E11-1CEC-4940-84B8-2AA432B2A679

P6179

Q33823085-F90FE173-1274-48D0-B9FA-B78446A296F5

P698

Q33823085-61F87882-663A-4319-90BB-AEC079E45C7F

P932

Q33823085-4A8CF483-4D03-43FC-BD73-66AC2AD86B87

P356

P1433

Nature Reviews Urology

P1476

Prostate cancer: estimating the benefits of PSA screening

@en

P2860

Mortality results from a randomized prostate-cancer screening trial

Screening and prostate-cancer mortality in a randomized European study

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study

The influence of finasteride on the development of prostate cancer.

Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique.

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.

The surgical learning curve for prostate cancer control after radical prostatectomy.

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

P2888

P304

301-303

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRUROL.2009.95

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Andrew J Vickers

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26268603

http://www.w3.org/2001/XMLSchema#string

P6179

1039220434

http://www.w3.org/2001/XMLSchema#string

P698

19498406

http://www.w3.org/2001/XMLSchema#string

P932

2862723

http://www.w3.org/2001/XMLSchema#string